Genomic assays are particularly beneficial in cancers where genetic mutations are known to drive disease progression. These include breast cancer, lung cancer, colorectal cancer, and melanoma, among others. For instance, in breast cancer, assays like the Oncotype DX test analyze the expression of a group of cancer-related genes to predict the risk of recurrence and the likely benefit of chemotherapy.
